1 / 19

NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS

NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news. Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE - GENERAL www.tumori.net/eurochip. WHAT IS THE EUROCHIP-2 THE ACTION PROJECT?.

keiran
Download Presentation

NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2THE ACTIONProject & news Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE - GENERAL www.tumori.net/eurochip

  2. WHAT IS THE EUROCHIP-2 THE ACTION PROJECT? • It is a translational research project (from epidemiology to public health) • It is a project against disparities • It is an EC project • It aims to research ways to promote health by EU imprimatur • Its goal is to promote public health actions against cancer in each EU country • It works in the building of an European platform for cancer control

  3. EUROPE WITHIN THE WORLD AGE-STANDARDIZED INCIDENCE RATES Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000

  4. EUROPE WITHIN THE WORLD AGE-STANDARDIZED MORTALITY RATES Source: GLOBOCAN 2002, IARC. Age-Standardised (World) rates, per 100,000

  5. All cancers combined: Europe

  6. Differences in Europe. Relative risks (Max/Min). All cancers combined Data from cancer registries of these countries Austria, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands,Norway,Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,Switzerland, United Kingdom Sources: EUROCIM - EUROCARE

  7. GDP (1997) and 5-year cancer survival Disks are proportional to the national health expenditure ($ PPP) $ PPP: Parity Purchasing Power per capita (US $) Sourcesi: OECD 2002 and EUROCARE-3

  8. EUROCHIP-1 INDICATOR A INDICATOR B INDICATOR C . . . INDICATOR Z INFORMATION Data available ANALYSIS Inequalities EUROCHIP-2 ACTIONS

  9. GENERAL AIMS OF EUROCHIP-2 • To extend the collaboration • To promote national groups in each country • To analyse the behaviour of available indicators • To discuss on deficiencies at national and international level • To promote at least one important ACTION in each country

  10. EUROCHIP-2: MAP

  11. EUROCHIP-2 DISCUSSION PLAN COUNTRY 1 COUNTRY 2 COUNTRY 3 COUNTRY 30 ACTION 2 ACTION 3 ACTION 4 ACTION 5 ACTION 6 ACTION 6 ACTION 1 ACTION 3 ACTION 4 EUROPEAN PUBLIC HEALTH ACTION – early diagnosis Cervical screening EUROPEAN PUBLIC HEALTH ACTION – care & treatment Pilot studies EUROPEAN PUBLIC HEALTH ACTION - prevention Dietary prevention EU CANCER PLAN

  12. UTERUS CANCER STANDARDIZED MORTALITY RATE AGE: 20 – 44 (IN THESE AGES MOSTLY CERVICAL CANCER) European standard per 100,000 EARLY DIAGNOSIS PILLAR 1 http://epicancer.iss.it

  13. EUROCHIP-2 ACTION: TASK FORCE ON CERVICAL CANCER SCREENING AIMS ACTION 1 • Describe the opportunistic/programmed cervical cancer screening in those countries at present time • For countries without cervical screening programs:find difficulties and problems with specific assessment studies in these Eastern European countries • For countries with cervical screening programs: to help specific activities that at the moment are not subsidize • To create relations with groups of pressure with national health ministries and with European Parliament • To share information with other networks (EUNICE, European Cancer Screening networks)

  14. ROMANIA ASSESSMENT PHASES: COLLECTION OF INFO ON Use of Policies, Guidelines, and Norms Program Management Issues Health Services Information and Education Activities Community Perspectives Laboratory Information Systems

  15. Screening prices VS treatment prices BULGARIA • In Bulgaria the mean value of programme screening for 1 person is around 5 € • Target population: 1.8 million (age 25-60) • Screening interval: 3 years • 5 € * 0.6 million = 3 million € per year BULGARIAN ESTIMATES V. Zlatkov - Bulgaria (2006)

  16. PROBLEMS OF THE ORGANISED SCREENING PROGRAM ESTONIA • Low participation: Only 21.7% of the 12,960 invited women attended the screening • No funds for screening registry • No invitation of women without insurance (~5% of population) • To use experience from other countries to produce successful campaigns • Group of pressure for invitation of women without insurance • Money for starting the organization of screening registry P. Veerus - Estonia (2006)

  17. EUROCHIP FUND • Budget: 17.500 € - Only for personnel costs • Involvement of personnel for ACTIONS • Money sent: • Directly to personnel OR • To Institute involved in the project • Necessary admin. documentation (at the end of the work) • Declaration of money receipt (by personnel) • Declaration of personnel payment (by Institute)

  18. EUROCHIP-2 FUNDS: THE ACTION IN LATVIA

More Related